Table 2.
Effect of resveratrol on hemorheological parameters.
| Baseline | 3rd month | ||||
|---|---|---|---|---|---|
| Control N = 20 |
Resveratrol N = 30 |
Placebo N = 30 |
Resveratrol N = 30 |
Placebo N = 30 |
|
| Hematocrit (%) | 43.35 ± 0.63 | 45.03 ± 0.98 | 44.93 ± 0.98 | 44.76 ± 0.93 | 44.10 ± 1.02 |
| WBV (mPas) | 4.04 ± 0.07 | 4.59 ± 0.13# | 4.55 ± 0.14# | 4.45 ± 0.13 | 4.42 ± 0.13 |
| PV (mPas) | 1.28 ± 0.02 | 1.34 ± 0.02 | 1.31 ± 0.02 | 1.32 ± 0.02 | 1.32 ± 0.02 |
| RBC aggregation (Myrenne) | |||||
| M | 5.91 ± 0.25 | 6.02 ± 0.36 | 6.38 ± 0.28 | 5.90 ± 0.31 | 6.36 ± 0.28 |
| M 1 | 13.77 ± 0.78 | 13.96 ± 0.42 | 14.14 ± .0.47 | 13.46 ± 0.40∗ | 13.84 ± 0.51 |
| RBC aggregation (LORCA) | |||||
| AI | 69.37 ± 1.1 | 73.36 ± 1.02# | 72.08 ± 1.04# | 70.55 ± 0.99∗ | 70.15 ± 1.14 |
| t 1/2 (s) | 1.57 ± 0.11 | 1.23 ± 0.08# | 1.34 ± 0.09# | 1.45 ± 0.08∗ | 1.51 ± 0.11 |
| γ (1/s) | 112.75 ± 4.43 | 161.92 ± 11.02# | 160.39 ± 12.54# | 133.70 ± 7.25∗ | 138.60 ± 9.12 |
Values are expressed as mean ± SEM. #Significant difference in the resveratrol or placebo groups compared to the control group at baseline; ∗significant difference in 3rd month values of the resveratrol group compared to the baseline values of the resveratrol group (p < 0.05). Baseline: measured values at randomization in the resveratrol group or in the placebo group; 3rd month: patients treated with resveratrol or placebo for 3 months; AI: aggregation index; t1/2 (s): aggregation half time; M and M1 values: aggregation indices at different rotation speeds of the aggregometer; PV: plasma viscosity; RBC: red blood cell; WBV: whole blood viscosity; γ (1/s): threshold shear rate.